On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Risk of Transfusion-Transmitted Babesiosis” guidance document with a maximum 12 month implementation timeline. Per the FDA guidance document recommendations, CTS is developing a specific implementation plan for mandatory Babesia testing well before the May 8, 2020 deadline.
Check out the Communication page for the complete details by clicking the link: Communications
The COVID-19 pandemic has unveiled the huge challenges and risks health workers are facing globally ...
On January 25, 2021, CTS implements the Ortho VIP viral marker testing platform. Conversion from the...
The recent communication regarding the recent Anti-SARS-CoV-2 Total assay in Tampa has brought about...
The revised CTS algorithm associated with the Ortho platform is now available for review. Clie...
CTS Dallas and Phoenix Labs successfully implemented WNV NAT testing on the Panther Testing Platform...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...